|Bid||175.54 x 800|
|Ask||175.54 x 800|
|Day's Range||175.40 - 175.99|
|52 Week Range||89.62 - 176.50|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||57.88|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 02, 1998|
|1y Target Est||177.75|
Varian (NYSE: VAR) today announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG (Frankfurt: SHL). Wilson will be succeeded by Chris Toth, President and Chief Operating Officer of Varian, who will become CEO of the Varian business segment of Siemens Healthineers upon the transaction close. Toth will report directly to Dr. Bernd Montag, Chief Executive Officer of Siemens Healthineers.
CTSI Oncology Solutions, a Varian (NYSE: VAR) company that provides oncology services for healthcare providers worldwide, has entered into a long-term, multi-year agreement with CHRISTUS Health, a Texas-based health system, to provide a broad spectrum of technology-enabled services in radiation oncology. Under the agreement, CTSI will provide six CHRISTUS radiation oncology departments with comprehensive support designed to increase efficiency, track and enhance quality, and reduce costs.
Varian (NYSE: VAR) announced it has joined the Cancer Drug Development Forum (CDDF) as an industry partner. This makes Varian the first medical technology company to join CDDF, the leading non-competitive drug development platform in Europe. CDDF's objective is to stimulate advancement in cancer drug development and access.